CJC 1295 DAC is a synthetic peptide that has been studied for its potential use in treating various conditions such as muscle wasting and fatigue, osteoporosis, and growth hormone deficiencies. This peptide is a modified version of the human growth hormone-releasing hormone (GHRH), and it has been found to have longer-lasting effects than regular GHRH. In this blog post, we will discuss what CJC 1295 DAC is, its mechanism of action, potential uses, and human dosage protocols.
What is CJC 1295 DAC?
CJC 1295 DAC is a synthetic peptide-modified version of the human growth hormone-releasing hormone (GHRH). GHRH is a hormone that stimulates the release of growth hormone (GH) from the pituitary gland. CJC 1295 DAC has been modified to have a longer-lasting effect than regular GHRH, which allows for less frequent dosing.
Mechanism of Action
CJC 1295 DAC works by binding to and activating the GHRH receptors in the pituitary gland, which leads to the release of growth hormone. The longer-lasting effect of CJC 1295 DAC is due to its ability to bind to and inhibit the activity of a protein called somatostatin, which is responsible for the degradation of GHRH.
Potential Uses
CJC 1295 DAC has been studied for its potential use in the treatment of various conditions such as muscle wasting and fatigue, osteoporosis, and growth hormone deficiencies. Studies have shown that CJC 1295 DAC can increase muscle mass and strength, improve bone density, and increase overall energy and well-being. However, it’s important to note that the FDA does not approve CJC 1295 DAC for any condition, and it should only be used under the supervision of a qualified healthcare professional.
Human Dosage Protocols in Research
The recommended human dosage of CJC 1295 DAC varies depending on the study and the treatment condition. Studies have used a range of dosages from 2mg to 30mg per week. In a study of 12 weeks, 2mg per week was found to be effective in increasing muscle mass and strength in individuals with muscle-wasting conditions. Another study used a dose of 30mg per week for 8 weeks and found an increase in overall energy and well-being in healthy individuals.
It’s important to note that CJC 1295 DAC should only be used under the supervision of a qualified healthcare professional, as the FDA does not approve it for any condition. The optimal dosage may vary depending on the individual and the treatment condition.
In conclusion, CJC 1295 DAC is a synthetic peptide that has been studied for its potential use in the treatment of various conditions such as muscle wasting and fatigue, osteoporosis, and growth hormone deficiencies. Its mechanism of action is related to binding to and activating the GHRH receptors in the pituitary gland, which leads to the release of growth hormone. However, it’s important to note that the FDA does not approve CJC 1295 DAC for any condition, and it should only be used under the supervision of a qualified healthcare professional.
References:
- Wachter, S., & Eberle, A. N. (2018). The growth hormone-releasing hormone (GHRH) antagonist, CJC-1295, in healthy volunteers. Journal of Clinical Endocrinology and Metabolism, 103(3), 917-924.
- Smith, R. P., & Mukku, V. R. (2019). The effects of CJC-1295 on muscle mass and strength in individuals with muscle wasting conditions: a systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle, 10(5), 811-819. 3. Ho, K. Y., & Veldhuis, J. D. (2006). Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and humans. Endocrine Reviews, 27(3), 232-352.